Insulet (NASDAQ:PODD) was downgraded by research analysts at BidaskClub from a “hold” rating to a “sell” rating in a research note issued on Thursday.

Several other equities analysts have also issued reports on PODD. Canaccord Genuity restated a “hold” rating and set a $50.00 price target on shares of Insulet in a research note on Wednesday, September 27th. Zacks Investment Research lowered Insulet from a “hold” rating to a “sell” rating in a research note on Thursday, October 5th. Wedbush reaffirmed a “buy” rating and set a $65.00 price objective (up from $60.00) on shares of Insulet in a report on Tuesday, October 10th. Leerink Swann reaffirmed an “outperform” rating and set a $74.00 price objective (up from $65.00) on shares of Insulet in a report on Thursday, October 12th. Finally, Robert W. Baird set a $65.00 price objective on Insulet and gave the company a “buy” rating in a report on Friday, October 13th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and twelve have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $62.53.

Insulet (PODD) opened at $72.91 on Thursday. Insulet has a 12 month low of $38.43 and a 12 month high of $78.65. The company has a debt-to-equity ratio of 4.65, a quick ratio of 4.42 and a current ratio of 4.88. The stock has a market capitalization of $4,400.16, a PE ratio of -145.82 and a beta of 1.58.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Thursday, November 2nd. The medical instruments supplier reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.06. Insulet had a negative return on equity of 43.85% and a negative net margin of 6.66%. The firm had revenue of $121.80 million for the quarter, compared to analyst estimates of $114.02 million. During the same period in the previous year, the company posted ($0.05) earnings per share. The company’s quarterly revenue was up 28.4% compared to the same quarter last year. equities analysts anticipate that Insulet will post -0.43 EPS for the current fiscal year.

In related news, Director James C. Mullen acquired 2,500 shares of the firm’s stock in a transaction on Monday, November 13th. The shares were bought at an average cost of $67.45 per share, with a total value of $168,625.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 2.60% of the stock is currently owned by insiders.

Several institutional investors and hedge funds have recently made changes to their positions in PODD. Schwab Charles Investment Management Inc. boosted its holdings in shares of Insulet by 3.4% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 252,670 shares of the medical instruments supplier’s stock worth $12,965,000 after acquiring an additional 8,399 shares in the last quarter. SG Americas Securities LLC acquired a new position in shares of Insulet in the 2nd quarter worth approximately $180,000. Bank of New York Mellon Corp boosted its holdings in shares of Insulet by 0.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 270,916 shares of the medical instruments supplier’s stock worth $13,901,000 after acquiring an additional 2,006 shares in the last quarter. Legal & General Group Plc boosted its holdings in shares of Insulet by 1.9% in the 2nd quarter. Legal & General Group Plc now owns 20,233 shares of the medical instruments supplier’s stock worth $1,034,000 after acquiring an additional 376 shares in the last quarter. Finally, Prudential Financial Inc. boosted its holdings in shares of Insulet by 42.0% in the 2nd quarter. Prudential Financial Inc. now owns 8,282 shares of the medical instruments supplier’s stock worth $425,000 after acquiring an additional 2,450 shares in the last quarter.

TRADEMARK VIOLATION NOTICE: “Insulet (PODD) Cut to “Sell” at BidaskClub” was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this article on another publication, it was illegally copied and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.watchlistnews.com/insulet-podd-cut-to-sell-at-bidaskclub/1811417.html.

About Insulet

Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).

Analyst Recommendations for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.